# Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)

> **NCT04480424** · PHASE2 · COMPLETED · sponsor: **Grifols Therapeutics LLC** · enrollment: 100 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** GAMUNEX-C
- **DRUG:** Standard Medical Treatment

## Key facts

- **NCT ID:** NCT04480424
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-17
- **Primary completion:** 2021-08-25
- **Final completion:** 2021-10-25
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2022-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04480424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04480424, "Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04480424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*